Background {#S0001}
==========

Breast cancer is the most common cancer in women in both developed and less developed countries. It is estimated that worldwide, over 627,000 women died in 2018 due to breast cancer.[@CIT0001] More than 14% of mortality causes in women in Iran are related to breast cancer.[@CIT0002] Although the incidence rate of breast cancer in Asian countries (such as Iran) is lower than in Western countries, the trend in Iran is rising.[@CIT0003] Breast cancer--survival rates differ considerably worldwide, ranging from 80% or over in North America, Sweden, and Japan to around 60% in middle-income countries and \<40% in low-income countries.[@CIT0004]

With regard to cancer, survival rate is considered one of the main prognostic indicators of the disease. In addition to various demographic factors, this index is influenced by the stage of cancer when diagnosed and the type of treatment, or in other words, diagnostic and therapeutic measures.[@CIT0005],[@CIT0006] Studies conducted in Iran's provinces over the past decade have estimated the 5-year survival rate in breast cancer patients to be 48%--87%.[@CIT0007] These differences may be due to patients' biological, racial/genetic, geographical, socioeconomic, and cultural differences, and also different treatment options and patients' access to these facilities.

The World Health Organization defines health as "a state of complete physical, mental, and social well-being, not merely the absence of disease or infirmity". Therefore, this is necessary to comprise an estimation of well-being, evaluated by quantifying advances in quality of life (QOL) related to health care, in addition to changes in the frequency and severity of diseases by measuring health and health-care consequences.[@CIT0008] Researchers have proposed that at least 80% of cancer patients, particularly those undergoing multiple treatments, experience notable levels of fatigue that may negatively affect their QOL, emotional well-being, and treatment tolerance.[@CIT0009] Some practical techniques for breast cancer patients' treatment are mastectomy, radiotherapy, and chemotherapy plus hormonal therapy. Although these effective treatment methods lead to increased survival rates in breast cancer patients, the QOL of such patients is fluctuating and often poor.[@CIT0010],[@CIT0011] For example, long-term radiotherapy or chemotherapy often results in loss of self-confidence, substantial disruption in physical functioning, mental health, and well-being, and impaired QOL. In addition, total or partial mastectomy could be one of the reasons of psychological and emotional problems such as depression and anxiety, all affect QOL of breast cancer patients.[@CIT0012],[@CIT0013]

CoQ~10~ is a lipophilic inner mitochondrial membrane cofactor with ten isoprenoid units that shuttle electrons in the formation of ATP, with wide distribution in the human body.[@CIT0014] Decreased critical levels of CoQ~10~ result in the reduction of energy production and antioxidant-protection capacity in cancer patients, due to two factors: cancer is more prevalent in older persons and CoQ~10~ synthesis declines with aging; and older cancer patients have multiple complications, such as oxidative stress, chemo/radiotherapy, and anticancer-drug usage, which lead to reductions in CoQ~10~ levels.[@CIT0015]

Studies on the effectiveness of CoQ~10~ on QOL in different diseases have indicated that this supplement can have a beneficial effect on QOL.[@CIT0016]--[@CIT0018] However, there have been few studies on breast cancer,[@CIT0009] and to our knowledge, a trial evaluating the effect of CoQ~10~ alone in breast cancer patients has not been done yet. Considering the high prevalence of breast cancer, in addition to its importance and effects on all life dimensions of patients, focusing on QOL as it relates to health and finding solutions to ameliorate QOL of these patients seems necessary. Therefore, we aimed to determine the efficacy of CoQ~10~ on QOL scores that had been collected in a double-blind randomized clinical trial for Iranian women with breast cancer.

Methods {#S0002}
=======

Patients {#S0002-S2001}
--------

The target population of this randomized double-blind placebo-controlled clinical trial was women diagnosed as breast cancer patients with positive estrogen receptor by their physicians. Patients entered the study from the Medical Oncology Department of the Governmental Shaffa Hospital, Ahvaz, Iran after meeting the inclusion criteria: age 19--49 years, at least 6 months since chemotherapy and radiation therapy, a history of taking 20 mg/day tamoxifen for at least 1 year, not taking CoQ~10~ supplements or other antioxidants, such as vitamin E, willingness to comply with all interventions and follow-up procedures, not pregnant or lactating, having no uncontrolled diseases, such as diabetes and thyroid disorders, and not taking nonprescription drugs, corticosteroids, or statins. Exclusion criteria comprised metastasis and total or partial mastectomy. There was no menstrual cycle in the patient/placebo group (14, 93.3%) or the patient/CoQ~10~ group (14, 93.3%) with the exception of one person in each group with regular menstrual cycles. All patients were at stage 1 or 2 breast cancer. Informed consent was received from all subjects after explanation of the study.

A total of 143 women diagnosed as breast cancer patients with positive estrogen receptor were assessed for eligibility, and 30 patients met the inclusion criteria. Subjects were divided into two groups using simple random sampling: 15 breast cancer patients received 100 mg/day CoQ~10~ orally (group A), and 15 breast cancer patients took 100 mg/day placebo (wheat flour encapsulated similarly in shape and color to the desired supplement, group B) for 2 months. For better absorption of supplements, subjects were advised to take them within meals, and compliance was calculated by counting the number of tablets given to each subject and recollected at the end of the trial. All procedures were performed at the Medical Oncology Department of Shaffa Hospital by the researchers, and patients were followed up by phone call weekly.

Assessment of Dietary Intake {#S0002-S2002}
----------------------------

A validated questionnaire and 3-day dietary record, including two weekdays and one weekend day, under supervision of a dietitian were completed by all subjects before and after the end of the study period. Dietary energy and nutrient intake were analyzed by Nutritionist IV software. Soy and soy products use were forbidden, because of estrogen-agonistic/antagonistic effects.[@CIT0019]

Assessment of Quality of Life {#S0002-S2003}
-----------------------------

The QOL of patients was evaluated using a standard QOL questionnaire (C30) and a specific questionnaire on QOL of breast cancer patients (BR23). The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 encompasses 30 items, including five functional scales (physical, role, emotional, cognitive, and social) and nine symptom scales (fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, constipation, diarrhea, financial difficulties) plus one global health scale. The BR23 questionnaire consists of 23 questions designed to quantify QOL in breast cancer, including five functional scales (body image, sexual functioning, sexual enjoyment, future perspectives), and four symptom scales (systematic therapy side effects, breast symptom, arm symptoms, upset about hair loss).[@CIT0020]

The EORTC QLQ was translated into Persian and validated by Safaee et al[@CIT0021] and Montazeri et al.[@CIT0022] In general, the findings of these studies indicated that the Iranian version of the EORTC QLQ-C30 and QLQ-BR23 were reliable and valid measures of QOL in breast cancer patients and can be used in clinical trials and studies of outcome research in oncology. After information collection from patients by QOL questionnaires, raw scores for each subscale were calculated and then changed to 0--100 scales according to the guidelines of the EORTC scoring manual. Higher scores on functioning scales and global health status indicate better QOL or a high level of functioning. In the case of symptom scales, higher scores indicate the higher levels of symptoms, a critical indicator of QOL.[@CIT0009] Physical activity was assessed by the International Physical Activity Questionnaire,[@CIT0023] which asks subjects about their physical activity in five sections: job-related, transportation, housework, recreation, and time spent sitting). In order to analyze this questionnaire, the relevant guidelines were used.[@CIT0024]

Sample Size {#S0002-S2004}
-----------

According to Premkumar et al, using Minitab software with 95% CI and test power of 90%, the sample size in each group was set at ten. To increase the accuracy of the study and to prevent a 50% drop, the sample size was increased to 15 individuals.

Statistical Analysis {#S0002-S2005}
--------------------

Data were analyzed with SPSS version 22. The Shapiro--Wilk test was used to specify the normality of the variables' distribution. The multi-item scales of EORTC QLQ-C30 and all subscales of BR23 were analyzed for relationships. ANCOVA and least significant--difference tests were applied to determine associations between study groups and independent/dependent variables measured before and after the trial. Dietary energy and nutrient intake were analyzed with Nutritionist IV. Values are presented as means ± SD, with significance set at *P*\<0.05.

Results {#S0003}
=======

Thirty patients (15 CoQ~10~ and 15 Placebo) completed the study. Some subject characteristics at the beginning of the study ([Table 1](#T0001){ref-type="table"}) were not significantly different between placebo and CoQ~10~ groups. Dietary intake of energy and macronutrients was assessed and showed no differences between groups at baseline and had not changed at the end of 2 months ([Table 2](#T0002){ref-type="table"}). Research has revealed that physical activity may affect CoQ~10~ plasma levels,[@CIT0025] and thus this was determined using the International Physical Activity Questionnaire ([Table 3](#T0003){ref-type="table"}). No significant difference was observed between groups.Table 1Anthropometric and Demographic Characteristics in Breast Cancer Patients in the StudyVariablesPlaceboCoQ~10~*P*-valuen=15n=15**Age (years)**36.33±7.7340.66±5.190.108**Height (cm)**158.26±2.40158.53±6.020.969**Weight (kg)**64.33±8.4665.26±8.430.901**Body-mass index (kg.m-2)**25.66±3.1525.96±3.010.250\***Educational**0.689 Illiterate2 (13.3%)6 (40%) Primary11 (73.3%)7 (46.7%) Secondary1 (6.7%)1 (6.7%) College/university1 (6.7%)1 (6.7%)**Marital status**0.857 Married14 (93.3%)13 (86.7%) Unmarried1 (6.7%)2 (13.3%)**Cigarette/alcohol**1 No14 (93.3%)14 (93.3%) Yes1 (6.7%)1 (6.7%)**Physical activity**1 Light15 (100%)14 (93.3%) Moderate01 (6.7%) Vigorous00[^1] Table 2Dietary Intake of Energy and Macronutrients in Breast Cancer Patients in the StudyVariablesBeforeAfter*P*-value\*Mean ± SDMean ± SD**Energy (kcal)**0.946 Patient/placebo2,044.46±355.902,058.46±341.95 Patient/CoQ~10~2,026.93±351.122,034.33±354.05**Protein (g)**0.192 Patient/placebo60.65±10±6661.65±10.85 Patient/CoQ~10~45.74±8.5849.04±10.16**Carbohydrates (g)**0.121 Patient/placebo279.70±46.52282.24±48.86 Patient/CoQ~10~296.77±54.23296.60±51.60**Fat (g)**0.111 Patient/placebo74.69±14.3974.47±13.19 Patient/CoQ~10~73.01±14.4575.16±15.57[^2] Table 3Physical Activity Levels of Breast Cancer Patients at Baseline and End Point of StudyVariablesBeforeAfter*P*-value(Mean ± SD)(Mean ± SD)Work domain**Walking, MET-minutes/week at work**0.234Patient/placebo92.40±243.84215.60±450.55Patient/CoQ~10~195.80±458.3646.20±178.93**Moderate MET-minutes/week at work**0.288Patient/placebo192±506.68856±2268.17Patient/CoQ~10~474.66±1541.04250.66±863.14**Vigorous MET-minutes/week at work**0.958Patient/placebo896±2364.531,133.33±4,334.20Patient/CoQ~10~56±216.8837.33±144.59**Total work, MET-minutes/week**0.541Patient/placebo1,180.40±3115.062,204.93±679.48Patient/CoQ~10~726.46±1927.19334.20±912.93Active transportation domain\***Walking, MET-minutes/week for transport**0.305Patient/placebo272.80±211.47595.10±1204.16Patient/CoQ~10~600.60±758.22262.90±240.44**Total transport, MET-minutes/week**0.305Patient/placebo272.80±211.47595.10±1204.16Patient/CoQ~10~600.60±758.22262.90±240.44Domestic and garden (yard work) domain**Vigorous MET-minutes/week yard chores**0.758Patient/placebo641.66±1616.08170.50±257.80Patient/CoQ~10~34.83±55.4560.50±149.97**Moderate MET-minutes/week yard chores**0.846Patient/placebo600±1125.39380±277.23Patient/CoQ~10~209.33±187.13220±168.69**Moderate MET-minutes/week inside chores**0.060Patient/placebo793±774.72552±450.54Patient/CoQ~10~658±664.77744±437.13**Total domestic and garden moderate MET-minutes/week**0.160Patient/placebo2,034.66±3461.931,102.50±884.95Patient/CoQ~10~902.16±807.451,024.50±604.86Leisure-time domain**Walking MET-minutes/week leisure**0.190Patient/placebo376.20±427.69311.30±194.51Patient/CoQ~10~227.70±234.52267.30±269.62**Moderate MET-minutes/week leisure**0.159Patient/placebo93.3±170.8237.33±83.44Patient/CoQ~10~10.66±28.14140±300.57**Vigorous MET-minutes/week leisure**0.549Patient/placebo56±149.5185.33±155.55Patient/CoQ~10~352±967.96320±877.91**Total leisure-time MET-minutes/week**0.249Patient/placebo525.53±593.27433.96±255.81Patient/CoQ~10~590.36±1038.92727.30±1068.82Sitting domain**Sitting, total minutes/week**0.060Patient/placebo1,457.33±1,180.591,541.53±1,127.93Patient/CoQ~10~1,988±1,005.741,776±826.66**Average sitting total minutes/day**0.060Patient/placebo208.19±168.65220.21±161.13Patient/CoQ~10~284±143.67253.71±118.09[^3]

[Tables 4](#T0004){ref-type="table"} and [5](#T0005){ref-type="table"} shows the effect of CoQ~10~ on QOL components during the two phases of measurement and their changes during the study. According to QOL C30 data, analysis of the questionnaires showed that supplementation with CoQ~10~ significantly increased physical functioning (*P*=0.029) compared to placebo. Also, emotional functioning and cognitive functioning of patients after supplementation significantly increased (*P*=0.031 and *P*=0.023, respectively). An insignificant increasing trend was observed on other functional scales, indicating better QOL than at the beginning of the study. Symptom scales revealed a notable reduction in appetite loss in the CoQ~10~ group (*P*=0.01). Global health status showed no significant changes in the CoQ~10~ or placebo arm. In the case of symptom scales, insignificant decreases were found in fatigue, nausea and vomiting, pain, insomnia, and constipation. However, financial problems increased significantly in the intervention group (*P*\<0.0001). On the QOL BR23, progress on functional scales (body image, sexual functioning, sexual enjoyment, and future perspectives) and decline on symptom scales (systemic therapy side effects, breast symptoms, and upset with hair loss) were not statistically significant. Arm symptoms (BRAS) showed significant reduction (*P*=0.022) in subjects receiving placebo.Table 4Effect of Coenzyme Q~10~ Supplementation on QOL C30 in Breast Cancer PatientsVariablesBeforeAfter*P*-value\*Mean ± SDMean ± SDDomains**Global health status/QOLQuestion 29**0.970Patient/placebo5.66±0.895.86±0.99Patient/CoQ~10~5.20±1.015.46±0.91**Question 30**0.770Patient/placebo5.93±0.706.13±1.12Patient/CoQ~10~5.40±1.055.73±0.96**Functional scalesPhysical functioning (PF2)**0.029Patient/placebo83.11±14.2284±12.54Patient/CoQ~10~78.66±15.9772.88±14.13**Role functioning (RF2)**0.309Patient/placebo94.44±8.1392.22±12.38Patient/CoQ~10~80±19.1086.66±18.03**Emotional functioning (EF)**0.031Patient/placebo83.88±13.5390±13.80Patient/CoQ~10~65.55±17.4980±12.51**Cognitive functioning (CF)**0.023Patient/placebo87.77±14.7294±12.06Patient/CoQ~10~75.55±15.2583.33±15.43**Social functioning (SF)**0.796Patient/placebo95.55±13.3193.33±13.80Patient/CoQ~10~91.11±20.7694±10.28**Symptom scales/itemsFatigue (FA)**0.149Patient/placebo14.07±18.5218.51±17.65Patient/CoQ~10~28.88±19.1528.14±20.08**Nausea and vomiting (NV)**0.153Patient/placebo16.66±43.180Patient/CoQ~10~10±16.423.33±9.34**Pain (PA)**0.787Patient/placebo14.44±17.6618.88±27.36Patient/CoQ~10~34.44±23.9521.11±18.32**Dyspnea (DY)**0.065Patient/placebo04.44±11.72Patient/CoQ~10~8.88±15.2520±30.34**Insomnia (SL)**0.811Patient/placebo13.33±27.6017.77±30.51Patient/CoQ~10~26.66±33.8015.55±21.33**Appetite loss (AP)**0. 010Patient/placebo6.66±18.6820±21.08Patient/CoQ~10~15.55±17.214.44±11.72**Constipation (CO)**\>0.999Patient/placebo22.22±24.122.22±8.60Patient/CoQ~10~15.55±21.332.22±8.60**Diarrhea (DI)**0.540Patient/placebo4.44±11.724.44±11.72Patient/CoQ~10~2.22±8.602.22±8.60**Financial difficulties (FI)**\<0.0001Patient/placebo42.22±38.7637.77±24.77Patient/CoQ~10~66.66±35.6380±27.60[^4] Table 5Effect of Coenzyme Q~10~ Supplementation on QOL Br23 in Breast Cancer PatientsVariablesBeforeAfter*P*-value\*Mean ± SDMean ± SDDomains**Functional scalesBody image (BRBI)**0.948Patient/placebo76.66±22.3171.11±27.43Patient/CoQ~10~65±20.7070.55±20.86**Sexual functioning (BRSEF)**0.951Patient/placebo32.22±7.6272.22±13.60Patient/CoQ~10~27.38±19.1771.79±23.94**Sexual enjoyment (BRSEE)**0.347Patient/placebo44.44±20.5722.22±24.12Patient/CoQ~10~23.80±24.2030.95±27.62**Future perspective (BRFU)**0.183Patient/placebo57.77±38.7655.55±34.88Patient/CoQ~10~62.22±27.7968.88±19.78**Symptom scales/itemsSystemic therapy side effects (BRST)**0.320Patient/placebo20.31±21.8518.73±17.76Patient/CoQ~10~27.61±10.2124.12±12.53**Breast symptoms (BRBS)**0.651Patient/placebo13.33±17.1913.33±21.77Patient/CoQ~10~8.33±7.7110.55±11.55**Arm symptoms (BRAS)**0.022Patient/placebo20±18.8714.81±20.85Patient/CoQ~10~18.874±18.2434.07±26.38**Upset by hair loss (BRHL)**0.232Patient/placebo11.11±27.2115.55±35.33Patient/CoQ~10~8.88±15.254.44±11.72[^5]

Discussion {#S0004}
==========

Cancer treatments, such as chemotherapy, in breast cancer patients can cause several side effects and symptoms, including physical, functional, psychological and social difficulties (anxiety, depression, pain, fatigue, and arm morbidity), that affect QOL. Clinical trials have demonstrated that evaluation of QOL and making changes leads to treatment improvement, increasing survival in cancer patients.[@CIT0026] It has been shown that numerous disease processes associated with CoQ~10~ deficiency can benefit from CoQ~10~ supplementation, including cancer. In this study, we evaluated the efficacy of CoQ~10~ on QOL in breast cancer patients.[@CIT0027]

The results of this study demonstrated that oral CoQ~10~ supplementation (100 mg/day) for 8 weeks had beneficial effects on physical, emotional, and cognitive functioning, as well as appetite. However, global health status remained unchanged after CoQ~10~ supplementation. Furthermore, there was a not-inconsiderable improvement in other dimensions of EORTC questionnaire scores in the supplemented group that showed nonstatistically significant but clinical importance of CoQ~10~ in ameliorating QOL. These outcomes were obtained despite the low sample size and short study duration, and for better understanding of CoQ~10~ effects on QOL of breast cancer patients, more clinical trials are needed.

Although the effects of CoQ~10~ on QOL among patients with other chronic diseases have been studied in several clinical trials with conflicting results, to our knowledge this is the first study indicating the effect of CoQ~10~ supplementation alone on QOL in patients with breast cancer. There have been some clinical trials done to assess the effect of CoQ~10~supplementation alone on QOL in breast cancer patients, and the their results were in line with our study.

Guilbot et al suggested that 12 weeks of a combination of feverfew, magnesium, and CoQ~10~ at a dosage of 100 mg/day for migraine prophylaxis significantly reduced the number of days with migraine headache and improved QOL.[@CIT0016] In another study, Sharifi et al showed that both a therapeutic lifestyle--change diet and supplementation with CoQ~10~ (150 mg/day) and L-carnitine had a positive effect on the physical and emotional subscales of the MacNew questionnaire in patients with myocardial infarction.[@CIT0017] In addition, Morris et al illustrated the CoQ~10~\'s potential role in improving QOL in patients with Parkinson's disease and fibromyalgia. Also, it showed antidepressive effects and significantly reduced fatigue and improved ergonomic performance during exercise.[@CIT0028] Other studies assessing the effect of CoQ~10~ in combination with other nutrients, such as NADH, in chronic fatigue syndrome[@CIT0029] and high-dose micronutrients in patients with chronic heart failure[@CIT0018] have indicated significant improvement in QOL and other dimensions of health care.

In contrast to our study, clinical trials have revealed conflicting results, eg, 300 mg/day CoQ~10~ or placebo, each combined with 300 IU vitamin E, divided into three daily doses for 24 weeks led to increase in plasma CoQ~10~ levels, but did not result in improved self-reported fatigue or QOL in breast cancer patients.[@CIT0009] Also, a study on amino-acid jelly containing CoQ~10~ and L-carnitine in controlling fatigue in breast cancer patients receiving chemotherapy showed that EORTC QLQ-C30, and EORTC QLQ-BR23 scores were not significantly different between the two groups.[@CIT0030] Muscle strength, muscle endurance, and QOL increased statistically significantly in all postpolio-syndrome patients in both groups of CoQ~10~ supplementation and placebo, which revealed CoQ~10~ had no beneficial effect.[@CIT0031]

Multiple roles as an antioxidant, a membrane stabilizer, and specifically mitochondria regulation, which optimize cell-energy generation, are some aspects of cellular CoQ~10~ functioning. Lowered CoQ~10~ levels are connected with high inflammation, oxidative/nitrosative stress, and dysfunction of mitochondria, which are activated by intracellular signaling pathways, including NFκB, MAPK, and JAK--STAT. As such, proteins and fatty acids in cell membranes can be attacked by ROS, which reduces membrane fluidity and diminishes the performance of cell-membrane receptors and ion channels, thus disrupting intercellular and intracellular signaling processes and leading to such disorders as fatigue, hyperalgesia, depression, and neurodegenerative processes.[@CIT0027],[@CIT0032],[@CIT0033] Also, in depleted levels of CoQ~10~, uncoupling proteins do not function correctly, which causes inability in regulating cellular fuel metabolism and other ATP-dependent processes.[@CIT0027],[@CIT0034] Some genes involved in mitochondrial biogenesis and replication due to increasing energy demands are under CoQ~10~ control. As a consequence, stimulating oxidative metabolism in response to increased demands for energy could be affected in CoQ~10~ deficiencys.[@CIT0035] CoQ~10~ treatment decreases fatigue, depression, and hyperalgesia through its anti-inflammatory, antioxidant, and neuroprotective effects. Also, it decreases muscle weakness, increases walking distance, and improves exercise tolerance and oxygen consumption by modification of the performance of complex I of the electron-transfer chain.[@CIT0028] Given that, sex and dietary intake are considered confounding factors in QOL.[@CIT0036],[@CIT0037] Limiting our sample to women and records of dietary intake are a couple of the strengths of our study.

Conclusion {#S0005}
==========

In this study, we discovered proof demonstrating significant effects of CoQ~10~ on physical, social, and mental conditions in women with breast cancer. In short, the supplemented patients showed better QOL at the end of the study. Separate studies should be conducted in different age-groups and larger populations for longer periods to generalize the evidence gained.
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[^1]: **Notes:** Anthropometric data given as mean ± SD and demographic data as n (%). Kruskal--Wallis test used for age, height, and weight, and *χ*^2^ used for other variables. \*Difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA.

[^2]: **Notes:** \*Difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA.

[^3]: **Notes:** *P*-values for difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA. Metabolic equivalent: 1 MET = 1 kcal/kg/hour). \*This section includes two areas of walking and cycling. Due to the negative response to participation in cycling, this area was removed in the data analysis.

[^4]: **Notes:** \*Difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA. *P*\<0.05 significant.

[^5]: **Notes:** \*Difference between treatment and placebo groups at follow-up and baseline visits using ANCOVA. *P*\<0.05 is significant.
